title: Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
abstract: We evaluated the association of circulating levels of heat shock protein 70 (Hsp70) in plasma with clinical behavior and progression in 139 chronic myeloid leukemia (CML) patients. Circulating Hsp70 levels did not differ significantly between CML patients in the chronic phase (n=93; median 33.24 ng/mL, range 3.89-128.2 ng/mL) and those in the accelerated/blast phase (n=46; median 26.57 ng/mL, range 4.5-114.7 ng/mL). However, overall CML patients had significantly higher levels of Hsp70 than healthy subjects (n=95, median 4.17 ng/mL, range 1.75-24.7 ng/mL) (P<0.001). In chronic phase CML patients, Hsp70 levels above the median were associated with a higher rate of progression to the accelerated/blast phase and a tendency toward shorter survival. Plasma Hsp70 thus could be a potential marker for predicting disease progression in patients with chronic phase CML.
authors: Department of Hematopathology, 33608 Ortega Highway, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, United States.
authors: Chen-Hsiung
authors: CH
authors: Yeh
authors: Richard
authors: R
authors: Tseng
authors: Zhong
authors: Z
authors: Zhang
authors: Jorge
authors: J
authors: Cortes
authors: Susan
authors: S
authors: O'Brien
authors: Francis
authors: F
authors: Giles
authors: Alison
authors: A
authors: Hannah
authors: Zeev
authors: Z
authors: Estrov
authors: Michael
authors: M
authors: Keating
authors: Hagop
authors: H
authors: Kantarjian
authors: Maher
authors: M
authors: Albitar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D018840:HSP70 Heat-Shock Proteins / Q000097:blood*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis*; D015465:Leukemia, Myeloid, Accelerated Phase / Q000175:diagnosis; D015466:Leukemia, Myeloid, Chronic-Phase / Q000175:diagnosis; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D001549:Benzamides; D015415:Biomarkers; D018840:HSP70 Heat-Shock Proteins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate